Sanofi-Aventis to acquire Genzyme?
It is rumoured that multinational drugmaker Sanofi-Aventis is to acquire US-based biotechnology company Genzyme, a manufacturer of vaccines for genetic disorders and producer of drugs such as Cerezyme, a treatment for Gaucher's disease, and Fabrazyme, for Fabry disease.
French pharmaceutical group Sanofi-Aventis has completed its acquisition of 100% of Chattem, a US-based provider of branded over-the-counter healthcare products, toiletries and dietary supplements, which is now a wholly owned subsidiary of the Sanofi-Aventis Group.